MDx Health has launched its new prostate cancer test. SelectMDx is designed to detect prostate cancer in urine samples, avoiding painful prostate biopsies when cancer is suspected.

Together with MRC Technology, Biocartis has announced a collaboration for the development of a liquid biopsy test for hormone treatment-resistant breast cancer.

At the 8th edition of MATWIN’s annual international board meeting PDC*Line Pharma was awarded with the prize of Most Promising Project in the start-up category.

With production GMP approved, Mithra's Myring contraceptive is well on schedule to storm the markets within less than a year.

To also serve geographies where BRAF testing is not reimbursed, Biocartis launches a new NRAS test next to their combined NRAS-BRAF assay.

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.